EUVIMEDEUVIMED entdecken
Open Access

Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma

Sara Viragova iD, Luis Aparicio iD, Pierangela Palmerini iD, Junfei Zhao iD, Luis E Valencia Salazar iD, Alexandra Schurer iD, Anika Dhuri, Debashis Sahoo iD, Christopher A Moskaluk iD, Raul Rabadan iD, Piero Dalerba iD

JNCI: Journal of the National Cancer Institute · 2023

DOI: 10.1093/jnci/djad062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2023. Verfasst von Sara Viragova und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Adenoid Cystic, Receptors, Retinoic Acid. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adenoid cystic carcinoma (ACC) is a lethal malignancy of exocrine glands, characterized by the coexistence within tumor tissues of 2 distinct populations of cancer cells, phenotypically similar to the myoepithelial and ductal lineages of normal salivary epithelia. The developmental relationship linking these 2 cell types, and their differential vulnerability to antitumor treatments, remains unknown.

Methods

Using single-cell RNA sequencing, we identified cell-surface markers (CD49f, KIT) that enabled the differential purification of myoepithelial-like (CD49fhigh/KITneg) and ductal-like (CD49flow/KIT+) cells from patient-derived xenografts (PDXs) of human ACCs. Using prospective xenotransplantation experiments, we compared the tumor-initiating capacity of the 2 cell types and tested whether one could differentiate into the other. Finally, we searched for signaling pathways with differential activation between the 2 cell types and tested their role as lineage-specific therapeutic targets.

Results

Myoepithelial-like cells displayed higher tumorigenicity than ductal-like cells and acted as their progenitors. Myoepithelial-like and ductal-like cells displayed differential expression of genes encoding for suppressors and activators of retinoic acid signaling, respectively. Agonists of retinoic acid receptor (RAR) or retinoid X receptor (RXR) signaling (all-trans retinoic acid, bexarotene) promoted myoepithelial-to-ductal differentiation, whereas suppression of RAR/RXR signaling with a dominant-negative RAR construct abrogated it. Inverse agonists of RAR/RXR signaling (BMS493, AGN193109) displayed selective toxicity against ductal-like cells and in vivo antitumor activity against PDX models of human ACC.

Conclusions

In human ACCs, myoepithelial-like cells act as progenitors of ductal-like cells, and myoepithelial-to-ductal differentiation is promoted by RAR/RXR signaling. Suppression of RAR/RXR signaling is lethal to ductal-like cells and represents a new therapeutic approach against human ACCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Adenoid CysticReceptors, Retinoic AcidHumansDrug Inverse AgonismProspective StudiesRetinoid X ReceptorsTretinoin

Substanzen

Antineoplastic AgentsReceptors, Retinoic AcidRetinoid X ReceptorsTretinoin

Autor:innen und Institutionen

  • Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.
  • Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
  • Columbia Stem Cell Initiative, Columbia University Medical Center, New York, NY, USA.
  • Integrated Program in Cellular, Molecular and Biomedical Studies, Columbia University, New York, NY, USA.
  • Program for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA.
  • Department of Biomedical Informatics, Columbia University, New York, NY, USA.

ORCID-Profile: Sara Viragova, Luis Aparicio, Pierangela Palmerini, Junfei Zhao, Luis E Valencia Salazar, Alexandra Schurer, Debashis Sahoo, Christopher A Moskaluk, Raul Rabadan, Piero Dalerba

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NCATS NIH HHS
  • NIDCR NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health
  • Adenoid Cystic Carcinoma Research Foundation
  • Damon Runyon Cancer Research Foundation

Zitieren

APA

Viragova, S., Aparicio, L., Palmerini, P., Zhao, J., Valencia Salazar, L. E., Schurer, A., Dhuri, A., Sahoo, D., Moskaluk, C. A., Rabadan, R., & Dalerba, P. (2023). Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djad062

Vancouver

Viragova S, Aparicio L, Palmerini P, Zhao J, Valencia Salazar LE, Schurer A, et al. Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma. JNCI: Journal of the National Cancer Institute. 2023. doi:10.1093/jnci/djad062

BibTeX
@article{Viragova2023,
  author = {Viragova, Sara and Aparicio, Luis and Palmerini, Pierangela and Zhao, Junfei and Valencia Salazar, Luis E and Schurer, Alexandra and Dhuri, Anika and Sahoo, Debashis and Moskaluk, Christopher A and Rabadan, Raul and Dalerba, Piero},
  title = {Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2023},
  doi = {10.1093/jnci/djad062}
}
Kostenlos starten →